Skip to main content
SpringerLink
Log in

Latest guidance from NICE

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. NICE consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C. Media Release : 15 Aug 2014. Available from: URL: https://www.nice.org.uk.

  2. NICE. NICE appraisal of earlier treatment with abiraterone for prostate cancer. Media Release : 14 Aug 2014. Available from: URL: http://www.nice.org.uk.

  3. NICE. More research needed on chemotherapy dose test My5-FU. Media Release : 14 Aug 2014. Available from: URL: http://www.nice.org.uk.

  4. NICE. NICE proposes to recommend lenalidomide for myelodysplastic syndromes. Media Release : 19 Aug 2014. Available from: URL: http://www.nice.org.uk.

  5. NICE. NICE recommends new tests for bleeding problems during and after cardiac surgery. Media Release : 19 Aug 2014. Available from: URL: http://www.nice.org.uk.

  6. The Institute of Cancer Research. Statement in response to rejection of abiraterone before chemotherapy in final draft guidance from NICE. Media Release : 14 Aug 2014. Available from: URL: http://www.icr.ac.uk.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Latest guidance from NICE. PharmacoEcon Outcomes News 710, 30 (2014). https://doi.org/10.1007/s40274-014-1503-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1503-x

Search

Navigation